Hoth Therapeutics (NASDAQ:HOTH) is a clinical-stage biopharmaceutical company focused on developing novel therapies across dermatology, immunology, ophthalmology and infectious disease. The company’s mission is to advance innovative treatments that address unmet medical needs through targeted drug delivery systems and proprietary formulations. Hoth Therapeutics leverages its expertise in topical, transdermal, and ocular delivery platforms to enhance safety, efficacy and patient compliance.
The company’s lead asset, HT-001, is a topical formulation designed to treat plaque psoriasis and other inflammatory skin disorders. Preclinical and early-stage clinical data have demonstrated its potential to reduce disease activity with a favorable safety profile. In the ophthalmology space, Hoth is advancing HT-102, an eye drop formulation intended to minimize post-surgical inflammation following cataract procedures, and IMM-001, which targets macular edema associated with diabetic retinopathy and retinal vein occlusion.
Founded in 2018 and headquartered in New York City, Hoth Therapeutics has assembled a management team with deep experience in pharmaceutical R&D, regulatory strategy and commercial development. Under the leadership of CEO Michael Goldstein, the company has established strategic collaborations with contract research organizations and manufacturing partners to support its pipeline. Hoth’s board and scientific advisory members bring decades of biotech and pharmaceutical expertise, helping to guide clinical programs and streamline regulatory pathways.
Hoth Therapeutics conducts its research and clinical trials primarily in North America, while exploring opportunities for global partnerships to expand access to its therapies. By focusing on diseases with high unmet medical needs and leveraging its proprietary delivery technologies, the company aims to advance multiple programs through proof-of-concept studies and into pivotal trials. Hoth continues to explore licensing and collaboration agreements to accelerate the development and commercialization of its pipeline assets.
